En Español
Xarelto is a popular prescription blood thinning medication used to treat or prevent stroke, deep vein thrombosis, and pulmonary edema. Recently, class action lawsuits have been filed on behalf of patients prescribed the medication claiming that patients were not warned of the increased chances of cranial and gastrointestinal bleeding when patients take the medication daily and are not properly monitored. A new study, recently, published has caused attorneys to appeal a recent bellwether trial, claiming the evidence, had it been available at the time, would have caused a different outcome, as the Penn Record reports.
This past August, a seven-person jury from the U.S. District Court for the Southern District of Mississippi ruled that Bayer and Janssen Pharmaceuticals, a Johnson and Johnson subsidiary were not liable in the death of 69-year-old Dora Mingo of Summit, Mississippi.
Witnesses for the defense testified that “no practical and effective lab test exists that would protect patients taking Xarelto from excessive bleeding and sometimes death. Further, the defense experts testified that a test called prothrombin time or PT was “meaningless” and “dangerous to use with Xarelto.”
Unknown at the time by Mingo’s attorneys, a medical study conducted and co-authored by Bayer scientists was published in the Journal of Thrombosis and Haemostasis, advocated the PT test as something that may be used to assess anticoagulant activity and was sensitive to Rivaroxaban. Rivaroxaban is the chemical name for the prescription drug Xarelto.
Andy Birchfield, leading co-counsel for Mingo, maintains that knowledge of this study would have led to a different outcome in court. They are seeing a new trial.
Have you been injured as a result of taking the prescription drug Xarelto? Let the law offices of John Foy & Associates fight to get you the compensation that you deserve. Call us today.
